See the DrugPatentWatch profile for ruxolitinib

Based on the information available, it is difficult to provide an exact date for when Apotex's generic version of ruxolitinib will be available. However, according to DrugPatentWatch.com, the patent for ruxolitinib (trade name Jakafi) expired in the United States on November 14, 2021 [1]. This means that other manufacturers, like Apotex, can now apply for approval to produce generic versions of the drug.

It's important to note that even after a patent expires, it can still take several months to a few years for generic versions of a drug to become available on the market. This is because generic manufacturers must still complete their own testing and regulatory approval process with the Food and Drug Administration (FDA) [2].

Apotex, a Canadian-based pharmaceutical company, has not released any official statements regarding the availability of their generic ruxolitinib [3]. Therefore, it is recommended to keep an eye on Apotex's official announcements or contact them directly for the most up-to-date information.

In summary, while the patent for ruxolitinib has expired, there is no official confirmation or date regarding when Apotex's generic version will be available. It can take several months to a few years for generic drugs to become available after a patent expires.

Sources:

[1] DrugPatentWatch.com, Ruxolitinib (Jakafi) Patent Expiration. <https://www.drugpatentwatch.com/patent/ruxolitinib-jakafi/>

[2] Food and Drug Administration, Generic Drugs: Questions and Answers. <https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers>

[3] Apotex, Corporate Website. <https://www.apotex.com/>